Dermatology Times has published a commentary arguing that untreated atopic dermatitis carries its own side-effect profile — one that extends well beyond the skin. The piece, titled "The Side Effect of Doing Nothing: Reframing Atopic Dermatitis as a Systemic Disease," pushes clinicians to treat AD as a systemic inflammatory condition rather than a compartmentalized skin complaint.

The framing matters for how dermatologists counsel patients. If AD is systemic, then leaving it uncontrolled isn't a neutral choice, and the commentary's title says so directly: inaction has consequences of its own.

Why call atopic dermatitis 'systemic'?

The repositioning rests on a now-standard body of evidence linking moderate-to-severe AD to inflammatory comorbidities. Clinicians writing in this space typically point to associations with allergic rhinitis, asthma, food allergy and eosinophilic esophagitis — the classic atopic march — plus emerging links to cardiovascular and metabolic disease and to mental health burden.

The Dermatology Times piece sits squarely in that conversation. Its contribution is rhetorical as much as scientific: it names the therapeutic vacuum — "doing nothing" — as an exposure with its own risk, the way cardiology treats untreated hypertension.

What does this change in the clinic?

For practice, the implication is earlier and more decisive intervention. That means:

• Treating persistent, moderate-to-severe AD promptly rather than cycling indefinitely through topical steroids
• Screening for atopic comorbidities and referring when asthma, rhinitis or food allergy surface
• Framing systemic therapy — biologics such as dupilumab or tralokinumab, or oral JAK inhibitors — as disease control, not escalation of last resort
• Counting mental health burden as part of the disease, not a separate problem

The commentary's logic also touches adherence. Patients who view AD as "just a rash" underinvest in treatment. A systemic framing gives them a reason to stay on therapy when the skin looks better but inflammation hasn't fully quieted.

Where the evidence conversation goes next

The systemic-AD argument has been building in the literature and at congress sessions for several years, and commentaries like this one aim to move it from academic discussion into everyday counseling. As targeted systemic agents multiply and long-term registries accumulate comorbidity data, expect the "side effect of doing nothing" to become a harder number to ignore in treatment discussions.